Nuvectis Pharma, Inc. (NVCT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 13.29M USD | Liabilities, Current |
| Cash and equivalents | 22.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $13.29M | $22.16M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $11.18M | $25.13M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $13.30M | $31.63M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $11.58M | $35.44M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $10.13M | $26.79M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $9.19M | $29.86M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $8.89M | $18.53M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $6.32M | $17.17M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $5.77M | $18.12M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $5.69M | $19.46M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $6.98M | $19.13M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $5.58M | $22.06M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $4.61M | $24.60M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $3.93M | $15.47M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.19M | $19.99M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $4.49M | $23.64M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $2.74M | $13.57M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $3.06M | $16.69M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $2.42M | $5.74M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |